Further considerations for venom immunotherapy following the withdrawal of Pharmalgen
Further considerations for venom immunotherapy following the withdrawal of Pharmalgen
1111-1112
Erlewyn-Lajeunesse, M
e1763b6d-165b-45c5-9108-5dc8722220b9
Alviani, C
32a5985d-da5c-48e4-a098-5374d3546e77
Cross, S
00f64fff-0310-4134-80bd-2dbf93c5ce27
Grainger-Allen, E
577feebc-0475-4a30-aa58-f594a86822b8
July 2020
Erlewyn-Lajeunesse, M
e1763b6d-165b-45c5-9108-5dc8722220b9
Alviani, C
32a5985d-da5c-48e4-a098-5374d3546e77
Cross, S
00f64fff-0310-4134-80bd-2dbf93c5ce27
Grainger-Allen, E
577feebc-0475-4a30-aa58-f594a86822b8
Erlewyn-Lajeunesse, M, Alviani, C, Cross, S and Grainger-Allen, E
(2020)
Further considerations for venom immunotherapy following the withdrawal of Pharmalgen.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 50 (9), .
(doi:10.1111/cea.13690).
This record has no associated files available for download.
More information
e-pub ahead of print date: 22 June 2020
Published date: July 2020
Identifiers
Local EPrints ID: 508168
URI: http://eprints.soton.ac.uk/id/eprint/508168
ISSN: 0954-7894
PURE UUID: d38ad6b5-40f1-40b9-8e96-2876f8353dab
Catalogue record
Date deposited: 14 Jan 2026 17:32
Last modified: 15 Jan 2026 02:55
Export record
Altmetrics
Contributors
Author:
M Erlewyn-Lajeunesse
Author:
C Alviani
Author:
S Cross
Author:
E Grainger-Allen
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics